Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- July15 2004
- Volume 11
- Issue 13
Leaders' Worth
Advertisement
$25 billion—Net worth of Saudi Arabian King Fahd.
$660 million—Net worth of British Queen Elizabeth II.
$200 million—Net worth of Palestinian Leadership Organization President Yasir Arafat.
$150 million—Net worth of Cuban President Fidel Castro.
$15 million—Net worth of US President George W. Bush.
$9 million—Net worth of French President Jacques Chirac.
$3 million—Net worth of British Prime Minister Tony Blair.
(Forbes, 2004)
Articles in this issue
about 18 years ago
Batten Down Your Inheritance Hatchesabout 18 years ago
Decide What to Do with Your IRA Assetsabout 18 years ago
Start Your Retirement Plan Immediatelyabout 18 years ago
Know when Less Is More and More Is Lessabout 18 years ago
Ease Worries of the Sandwich Generationabout 18 years ago
Uncover the Fine Print on Annuitiesabout 18 years ago
Impart Memories Before They Are Goneabout 18 years ago
Rent Real Estate as an Investment Optionabout 18 years ago
Find the Right Mortgage Lender for Youabout 18 years ago
Renovate Without Building Property TaxAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5